Company / Capital Expenditures
Taysha Gene Therapies, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$738.0K
FY2025
5-year range
$738.0K / $20.6M
FY2021-FY2025
Trend
-80.9%
vs FY2024
Sector context
#124 of 194
Health Care
What the data says
At $738,000, Taysha Gene Therapies, Inc.'s capital expenditures ranks #124 of 194 in the Health Care sector. Declined from $21M to $738,000 over the past 2 years.
Based on SEC 10-K filings.
$738,000 in FY2025 with a 5-year CAGR of +55.2%.
Declined from $21M to $738,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -63.6%
- 5-Year CAGR
- +55.2%
- 10-Year CAGR
- -
Sector benchmark
#124 of 194 in Health CareTop 64% of 194This company $738.0K Sector average $117.5M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +55.2%, indicating consistent growth.
- In FY2025, capital expenditures decreased 80.9% year-over-year.
- Ranks #124 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $738.0K | -80.9% |
| FY2024 | $3.9M | -81.2% |
| FY2023 | $20.6M | +34.7% |
| FY2022 | $15.3M | +0.0% |
| FY2021 | $15.3M | +18563.4% |
| FY2020 | $82.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026